Nothing Special   »   [go: up one dir, main page]

SK287111B6 - Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním - Google Patents

Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním Download PDF

Info

Publication number
SK287111B6
SK287111B6 SK749-2000A SK7492000A SK287111B6 SK 287111 B6 SK287111 B6 SK 287111B6 SK 7492000 A SK7492000 A SK 7492000A SK 287111 B6 SK287111 B6 SK 287111B6
Authority
SK
Slovakia
Prior art keywords
tolterodine
serum
controlled release
metabolite
water
Prior art date
Application number
SK749-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK7492000A3 (en
Inventor
Lisbeth Nilvebrant
Bengt Hall�N
Birgitta Olsson
Jan Str�Mbom
Bo Kreilgard
Jacobsen Orup
Ulla Hoeck
Helle Kristensen
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287111(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of SK7492000A3 publication Critical patent/SK7492000A3/sk
Publication of SK287111B6 publication Critical patent/SK287111B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SK749-2000A 1998-08-27 1999-08-26 Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním SK287111B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (2)

Publication Number Publication Date
SK7492000A3 SK7492000A3 (en) 2001-02-12
SK287111B6 true SK287111B6 (sk) 2009-12-07

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
SK749-2000A SK287111B6 (sk) 1998-08-27 1999-08-26 Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním

Country Status (31)

Country Link
US (1) US6770295B1 (cs)
EP (2) EP2153825A1 (cs)
CN (1) CN1239152C (cs)
AP (1) AP1529A (cs)
AR (1) AR029311A1 (cs)
AT (1) ATE487471T1 (cs)
AU (1) AU745190B2 (cs)
BG (1) BG65168B1 (cs)
CA (1) CA2311755C (cs)
CY (1) CY1111088T1 (cs)
CZ (1) CZ302630B6 (cs)
DE (1) DE69942928D1 (cs)
DK (1) DK1039882T3 (cs)
EA (1) EA002720B1 (cs)
GE (1) GEP20043354B (cs)
HK (1) HK1034664A1 (cs)
HU (1) HUP0100437A3 (cs)
ID (1) ID25824A (cs)
IL (1) IL136294A (cs)
IS (1) IS2976B (cs)
ME (1) ME00850B (cs)
MY (1) MY127946A (cs)
NO (1) NO329830B1 (cs)
NZ (1) NZ504618A (cs)
OA (1) OA11636A (cs)
PT (1) PT1039882E (cs)
SI (1) SI1039882T1 (cs)
SK (1) SK287111B6 (cs)
TR (1) TR200001998T1 (cs)
UA (1) UA72882C2 (cs)
WO (1) WO2000012069A1 (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
WO2001034139A1 (en) * 1999-11-11 2001-05-17 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
EP1441707A1 (en) * 2001-11-09 2004-08-04 Pharmacia AB Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1572173B1 (en) * 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta ligand to treat lower urinary tract symptoms
ATE432070T1 (de) * 2003-01-22 2009-06-15 Pfizer Health Ab Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
ES2359375T3 (es) 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. Formas de dosificación de dosis única diaria de trospio.
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2243475B1 (en) 2005-04-06 2016-01-13 Adamas Pharmaceuticals, Inc. Combination of memantine and donepezil for treatment of CNS disorders
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
DK1993559T3 (en) 2006-02-03 2016-10-03 Opko Renal Llc Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
EP2037936B1 (en) 2006-06-21 2014-06-11 Proventiv Therapeutics, LLC Method of treating and preventing secondary hyperparathyroidism
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
PT3342405T (pt) 2007-04-25 2019-12-02 Opko Ireland Global Holdings Ltd Libertação controlada 25-hidroxivitamina d
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
WO2012017892A1 (ja) * 2010-08-03 2012-02-09 久光製薬株式会社 貼付剤及びその粘着力増強方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3436026A1 (en) 2016-03-28 2019-02-06 OPKO Ireland Global Holdings, Ltd. Methods of vitamin d treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
JP3786684B2 (ja) * 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6310103B1 (en) * 1996-07-19 2001-10-30 Bridge Pharma, Inc. S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
WO1998011888A1 (en) * 1996-09-19 1998-03-26 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
AU745190B2 (en) 2002-03-14
IL136294A0 (en) 2001-05-20
DK1039882T3 (da) 2011-01-24
IL136294A (en) 2004-02-08
IS2976B (is) 2017-07-15
CA2311755C (en) 2010-03-23
HK1034664A1 (en) 2001-11-02
UA72882C2 (uk) 2005-05-16
IS5537A (is) 2000-06-15
AR029311A1 (es) 2003-06-25
CZ20001924A3 (cs) 2001-04-11
CY1111088T1 (el) 2015-06-11
MY127946A (en) 2007-01-31
CN1239152C (zh) 2006-02-01
ME00850B (me) 2008-08-07
HUP0100437A3 (en) 2002-08-28
AP1529A (en) 2006-01-03
CZ302630B6 (cs) 2011-08-10
EP2153825A1 (en) 2010-02-17
NO20002977D0 (no) 2000-06-09
CA2311755A1 (en) 2000-03-09
TR200001998T1 (tr) 2001-01-22
SK7492000A3 (en) 2001-02-12
DE69942928D1 (de) 2010-12-23
BG65168B1 (bg) 2007-05-31
EP1039882B1 (en) 2010-11-10
WO2000012069A1 (en) 2000-03-09
SI1039882T1 (sl) 2011-01-31
CN1287484A (zh) 2001-03-14
ID25824A (id) 2000-11-09
ATE487471T1 (de) 2010-11-15
NZ504618A (en) 2002-09-27
EP1039882A1 (en) 2000-10-04
AU5891899A (en) 2000-03-21
GEP20043354B (en) 2004-04-13
PT1039882E (pt) 2011-01-03
EA002720B1 (ru) 2002-08-29
US6770295B1 (en) 2004-08-03
NO329830B1 (no) 2011-01-03
HUP0100437A2 (hu) 2002-05-29
AP2000001823A0 (en) 2000-06-30
NO20002977L (no) 2000-06-09
EA200000468A1 (ru) 2000-12-25
OA11636A (en) 2004-09-03
BG104476A (en) 2000-12-29

Similar Documents

Publication Publication Date Title
US6770295B1 (en) Therapeutic formulation for administering tolterodine with controlled release
US6630162B1 (en) Pharmaceutical formulation and its use
TWI222879B (en) Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
ES2353765T3 (es) Formulación terapeútica para administrar tolterodina con liberación controlada.
US7829121B2 (en) Modified release dosage forms of skeletal muscle relaxants
MXPA00005215A (en) Therapeutic formulation for administering tolterodine with controlled release
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20190826